Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Aurore Iltis"'
Autor:
Delphine Loirat, Marie Duboys de la barre, Jean-Christophe Thery, Ioana Hrab, Christelle Jouannaud, Jean-Loup Mouysset, Laura Salabert, Pauline Soibinet, Audrey Mailliez, Romain Valery, Anne Creisson, Cristian Villanueva, Nadine Dohollou, Jean-david Fumet, Thomas grellety, Nathalie Perez-staub, Emma Lachaier, Aurore Iltis-roux, Miguel delbado, Abeer Najem, Romuald Le Scodan, Elsa Curtit, kais aldabbagh, Pascal Pujol, thibault DE LA MOTTE ROUGE
Publikováno v:
Cancer Research. 83:P4-01
Background: Talazoparib (TALA) is a highly potent, dual-mechanism PARP inhibitor that has demonstrated clinical benefit in EMBRACA Phase III trial for patients with germline BRCA1/2 mutated locally advanced or metastatic HER2- breast cancer. Objectiv
Publikováno v:
Clinical Nuclear Medicine. 45:e373-e375
We report the case of a 23-year-old man with nodal EMH (extramedullary hematopoiesis) occurring during treatment for a stage IIA "gray-zone" lymphoma. Although it is often related to myeloproliferative bone marrow disease, benign etiologies such as l
Autor:
Emmanuel Gyan, J. F. Tournamille, Emmanuel Bachy, Floriane Tixier, Florence Ranchon, Aurore Iltis, Gilles Salles, Catherine Rioufol, Clémentine Sarkozy, Nicolas Vantard, Vérane Schwiertz, Fadhela Bouafia-Sauvy
Publikováno v:
Hematological Oncology
Hematological Oncology, Wiley, 2017, 35 (4), pp.584-590. ⟨10.1002/hon.2328⟩
Hematological Oncology, Wiley, 2017, 35 (4), pp.584-590. ⟨10.1002/hon.2328⟩
International audience; Optimal salvage chemotherapy regimen for patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma remains unclear but often based on platinum regimens. This retrospective study assesses in real life the toxicities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209b3dac6d1eacf005dd762db37d013a
https://hal-univ-lyon1.archives-ouvertes.fr/hal-01796180
https://hal-univ-lyon1.archives-ouvertes.fr/hal-01796180
Autor:
Jérôme Bourgeais, Marie-Véronique Demattei, Emmanuel Gyan, Fabien Guilloton, Thomas Charbonnier, Karin Tarte, Jean-Claude Chomel, Aurore Iltis, Jorge Domenech, Laura Desbourdes, Nicole Ishac, Florence Rouleux-Bonnin, Olivier Herault, Joaquim Javary, Ali G. Turhan, Elfi Ducrocq
Publikováno v:
Stem Cells and Development
Stem Cells and Development, Mary Ann Liebert, 2017, 26 (10), pp.709-722. ⟨10.1089/scd.2016.0295⟩
Stem Cells and Development, 2017, 26 (10), pp.709-722. ⟨10.1089/scd.2016.0295⟩
Stem Cells and Development, Mary Ann Liebert, 2017, 26 (10), pp.709-722. ⟨10.1089/scd.2016.0295⟩
Stem Cells and Development, 2017, 26 (10), pp.709-722. ⟨10.1089/scd.2016.0295⟩
International audience; Bone marrow (BM)-derived mesenchymal stromal cells (MSCs) frequently display alterations in several hematologic disorders, such as acute lymphoid leukemia, acute myeloid leukemia (AML), and myelodysplastic syndromes. In acute
Publikováno v:
Acta Haematologica. 133:172-178
Background/Aims: An early evaluation with positron emission tomography (FDG-PET) has been demonstrated to be a valuable tool in the prediction of Hodgkin lymphoma's outcome. Herein we report a retrospective study on the outcome of Hodgkin lymphoma tr
Publikováno v:
Acta haematologica. 133(2)
An early evaluation with positron emission tomography (FDG-PET) has been demonstrated to be a valuable tool in the prediction of Hodgkin lymphoma's outcome. Herein we report a retrospective study on the outcome of Hodgkin lymphoma treated in accordan
Autor:
Aurore Iltis, Laura Desbourdes, Elfi Ducrocq, Olivier Herault, Emmanuel Gyan, Jorge Domenech, Thomas Charbonnier, Nicole Ishac
Publikováno v:
Blood. 122:2662-2662
Introduction The contribution of the stromal cell compartment to leukemogenesis remains poorly understood. Several studies have described abnormalities involving this compartment in acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS) in